Fangzhou Inc. signed a Memorandum of Understanding with Novo Nordisk at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity. By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service.
This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. The aim is to shift the focus from a "d disease-centered" approach to a "health-centered" model, providing patients with higher quality and more convenient one-stop healthcare services. Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the "Healthy China 2030" strategic objectives.
